AGL — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-06

• •inaccuracy in estimates of our members’ risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts;

• •non-compliance with the New York Stock Exchange could result in a delisting of our securities;

• •Total revenue of $1.4 billion decreased 7% from three months ended March 31, 2025.

• •Gross profit of $65 million, compared to $51 million in three months ended March 31, 2025.

• •Medical margin of $149 million, compared to $128 million in three months ended March 31, 2025.

Text removed vs the prior filing · source: 10-Q · 2025-11-04

• •inaccuracy in estimates of our members’ risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts;

• •Medicare Advantage members of approximately 502,800 as of September 30, 2025 decreased 4% from September 30, 2024.

• •CMS ACO Models (defined below) attributed beneficiaries of approximately 115,300 as of September 30, 2025 decreased 13% from September 30, 2024.

• •Total revenue of $1.4 billion decreased 1% from the third quarter of 2024.

• •Gross profit of negative $68 million, compared to negative $64 million in the third quarter of 2024.

Text added vs the prior filing · source: 10-Q · 2026-05-06

• We may be unable to comply with the continued listing requirements of the NYSE, which could result in the delisting of our common stock and have an adverse impact on the trading, liquidity and market price of our common stock.

• The Company’s common stock is currently traded on the New York Stock Exchange (“NYSE”) under the symbol “AGL”. The NYSE requires listed companies to satisfy continued listing standards, including a minimum average closing price of $1.00 per share of its common stock (the “Price Criteria for Capital …

• On November 5, 2025, the Company received written notice from the NYSE that it is not in compliance with the Price Criteria for Capital or Common Stock because the average closing price of its common stock was less than $1.00 per share over a consecutive 30 trading-day period ended November 4, 2025.…

• Despite regaining compliance, there can be no assurance that the Company will continue to meet the minimum share price requirement or any of the NYSE’s other continued listing standards in the future. Our stock price may decline for many reasons, including the performance of our business and financi…

• If we are unable to satisfy the Price Criteria for Capital or Common Stock or any other NYSE criteria for continued listing, our common stock would be subject to delisting. A delisting of our common stock could negatively impact us by, among other things, decreasing the amount of news and analyst co…

Text added vs the prior filing · source: 10-Q · 2026-05-06

• On November 5, 2025, we received notice from the NYSE that we were not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of our common stock was less than $1.00 per share over a consecutive 30 trading-day period. On March 30, 2026, we effected a 1…

• During the three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified, or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as such terms are defined in Item 408 of Regulation S-…

Text removed vs the prior filing · source: 10-Q · 2025-11-04

• During the three months ended September 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as such terms are defined in Item 408 of Regulation S-K under…